title: Disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment.
abstract: Abnormal mesolimbic control of cortical cholinergic activity has been hypothesized to contribute to the cognitive symptoms of schizophrenia. Stimulation of NMDA receptors in nucleus accumbens (NAC) increases acetylcholine (ACh) release in prefrontal cortex (PFC), an activation thought to contribute to attentional processing. Thus, the effects of intra-NAC perfusion of NMDA (250-400 microM) on ACh release in PFC were determined in rats receiving lesions of the ventral hippocampus (VH) as neonates (nVHLX), a neurodevelopmental model of schizophrenia, or as adults (aVHLX). NMDA elevated ACh release (100-150% above baseline) in adults sham-lesioned as neonates or in aVHLX rats. Adult nVHLX were unresponsive to NAC NMDA receptor stimulation. The inability of nVHLX to respond to NMDA emerged over development as a separate experiment demonstrated that evoked ACh release was normal before puberty (100-150% increase) yet, in these same nVHLX animals, absent after puberty. Amphetamine-evoked ACh release was assessed in nVHLX animals to exclude potential limitations in release capacity. Amphetamine produced greater increases in ACh release than in shams, indicating that nVHLX does not impair the capacity of cholinergic neurons to release ACh. Finally, the ability of 13 days of pretreatment with clozapine (1.25 mg/kg/day) to reinstate NMDA-evoked cortical ACh efflux was determined. Clozapine treatment normalized NMDA-evoked ACh release in nVHLX animals. These experiments show that mesolimbic regulation of cortical ACh release is disrupted in postpubertal nVHLX rats and normalized by low-dose treatment of clozapine; supporting the usefulness of nVHLX animals for research on the neuronal mechanisms underlying the cognitive symptoms of schizophrenia.
authors.affiliation: Department of Psychology, The Ohio State University, Columbus, OH 43210, USA.
authors.forename: Kathleen S
authors.initials: KS
authors.lastname: Alexander
authors.forename: Julie M
authors.initials: JM
authors.lastname: Brooks
authors.forename: Martin
authors.initials: M
authors.lastname: Sarter
authors.forename: John P
authors.initials: JP
authors.lastname: Bruno
mesh_terms: D000109:Acetylcholine / Q000378:metabolism*; D000375:Aging; D000661:Amphetamine / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D003024:Clozapine / Q000494:pharmacology*; D004195:Disease Models, Animal; D006624:Hippocampus / Q000503:physiopathology*; D007051:Ibotenic Acid; D008297:Male; D008845:Microinjections; D016202:N-Methylaspartate / Q000008:administration & dosage / Q000494:pharmacology; D009434:Neural Pathways / Q000503:physiopathology*; D009714:Nucleus Accumbens / Q000187:drug effects; D017397:Prefrontal Cortex / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012559:Schizophrenia / Q000139:chemically induced / Q000503:physiopathology*; D013997:Time Factors
chemical_list: D007051:Ibotenic Acid; D016202:N-Methylaspartate; D000661:Amphetamine; D003024:Clozapine; D000109:Acetylcholine
references.citation: Neuroscience. 2000;96(4):675-85
references.pmid: 10727786
references.citation: Biol Psychiatry. 2004 May 15;55(10):1013-22
references.pmid: 15121486
references.citation: Neuropsychopharmacology. 2007 Oct;32(10):2074-86
references.pmid: 17299502
references.citation: Eur J Neurosci. 2008 Feb;27(3):654-70
references.pmid: 18279318
references.citation: Brain Res. 1992 Jan 20;570(1-2):92-101
references.pmid: 1617433
references.citation: J Neurochem. 2004 Apr;89(2):314-23
references.pmid: 15056275
references.citation: J Neurochem. 1983 Jul;41(1):188-94
references.pmid: 6864218
references.citation: Neurobiol Learn Mem. 2008 Sep;90(2):339-46
references.pmid: 18490183
references.citation: Neuropsychopharmacology. 1996 Dec;15(6):587-94
references.pmid: 8946433
references.citation: Synapse. 2007 Mar;61(3):115-23
references.pmid: 17146770
references.citation: J Neurosci. 1995 May;15(5 Pt 1):3622-39
references.pmid: 7751934
references.citation: Behav Neurosci. 1996 Apr;110(2):247-65
references.pmid: 8731052
references.citation: Pharmacol Ther. 2009 May;122(2):150-202
references.pmid: 19269307
references.citation: Neuropsychopharmacology. 2005 Nov;30(11):1986-95
references.pmid: 15900318
references.citation: Psychopharmacology (Berl). 2009 Jan;202(1-3):237-58
references.pmid: 18618100
references.citation: Brain Res. 1982 May 13;239(2):401-15
references.pmid: 6284305
references.citation: Neuroscience. 2003;122(3):669-76
references.pmid: 14622910
references.citation: Schizophr Res. 2004 Dec 15;72(1):29-39
references.pmid: 15531405
references.citation: Psychopharmacology (Berl). 1995 Nov;122(1):35-43
references.pmid: 8711062
references.citation: Brain Res. 1998 Jun 22;797(1):73-93
references.pmid: 9630528
references.citation: Neuropharmacology. 2007 Sep;53(3):455-63
references.pmid: 17681559
references.citation: Brain Res Cogn Brain Res. 2000 Jun;9(3):313-25
references.pmid: 10808142
references.citation: Neuroscience. 1987 Oct;23(1):103-20
references.pmid: 3683859
references.citation: Am J Psychiatry. 2003 Jan;160(1):118-27
references.pmid: 12505810
references.citation: J Neurosci. 2008 Nov 26;28(48):12691-9
references.pmid: 19036962
references.citation: Schizophr Bull. 2005 Oct;31(4):830-53
references.pmid: 16177277
references.citation: Neuropsychopharmacology. 2008 Oct;33(11):2635-47
references.pmid: 18094665
references.citation: J Chem Neuroanat. 2001 Jul;22(1-2):53-63
references.pmid: 11470554
references.citation: Biol Psychiatry. 2008 Jul 1;64(1):26-33
references.pmid: 18549874
references.citation: Cereb Cortex. 2000 Dec;10(12):1168-75
references.pmid: 11073866
references.citation: Brain Res Brain Res Rev. 2000 Mar;31(2-3):330-41
references.pmid: 10719160
references.citation: Brain Res Brain Res Rev. 2005 Feb;48(1):98-111
references.pmid: 15708630
references.citation: Cereb Cortex. 2006 Jan;16(1):9-17
references.pmid: 15788700
references.citation: Cereb Cortex. 2002 Sep;12(9):975-82
references.pmid: 12183396
references.citation: Schizophr Bull. 1984;10(2):160-203
references.pmid: 6729409
references.citation: J Comp Neurol. 1996 Oct 28;374(4):555-77
references.pmid: 8910735
references.citation: J Chromatogr B Biomed Appl. 1995 Aug 18;670(2):323-7
references.pmid: 8548023
references.citation: Biol Psychiatry. 2004 Jan 15;55(2):172-6
references.pmid: 14732597
references.citation: Eur J Neurosci. 2005 Oct;22(7):1731-40
references.pmid: 16197513
references.citation: Psychopharmacology (Berl). 2004 Nov;176(3-4):312-9
references.pmid: 15179541
references.citation: Synapse. 2009 Mar;63(3):173-80
references.pmid: 19086088
references.citation: J Neurosci. 2002 Mar 1;22(5):1905-13
references.pmid: 11880520
references.citation: J Pharmacol Exp Ther. 2002 Sep;302(3):1135-45
references.pmid: 12183673
references.citation: J Neurosci. 2002 Oct 15;22(20):9070-7
references.pmid: 12388614
references.citation: Brain Res Rev. 2006 Aug;51(2):145-60
references.pmid: 16530842
references.citation: Neuropsychopharmacology. 1993 Aug;9(1):67-75
references.pmid: 8397725
references.citation: Biol Psychiatry. 2006 Sep 15;60(6):585-90
references.pmid: 16780812
references.citation: J Comp Neurol. 1988 Jul 8;273(2):263-82
references.pmid: 3417904
references.citation: Psychopharmacology (Berl). 2004 Jun;174(1):75-85
references.pmid: 15118804
references.citation: Psychopharmacology (Berl). 2004 Jun;174(1):86-98
references.pmid: 15071717
references.citation: Neuropsychopharmacology. 2003 Oct;28(10):1799-809
references.pmid: 12784101
references.citation: J Neurosci. 2004 Feb 4;24(5):1040-9
references.pmid: 14762122
references.citation: Biol Psychiatry. 2007 Oct 1;62(7):730-8
references.pmid: 17207473
references.citation: Neuroscience. 2005;133(2):463-70
references.pmid: 15878241
references.citation: J Pharmacol Exp Ther. 2003 May;305(2):625-31
references.pmid: 12606608
references.citation: Schizophr Bull. 2009 Jan;35(1):109-14
references.pmid: 19023126
references.citation: Schizophr Bull. 2005 Jan;31(1):117-38
references.pmid: 15888431
references.citation: Behav Pharmacol. 2000 Jun;11(3-4):257-68
references.pmid: 11103880
references.citation: Psychophysiology. 1987 Jul;24(4):479-86
references.pmid: 3615759
references.citation: Neuropsychopharmacology. 2002 Mar;26(3):325-39
references.pmid: 11850147
references.citation: Eur J Neurosci. 2003 Jul;18(2):391-402
references.pmid: 12887421
references.citation: Ann N Y Acad Sci. 1999 Jun 29;877:339-67
references.pmid: 10415658
references.citation: Schizophr Res. 2009 Sep;113(2-3):298-307
references.pmid: 19500946
references.citation: Schizophr Bull. 2009 Jan;35(1):182-96
references.pmid: 19074499